ACC 2024: Obicetrapib Works Synergistically with Ezetimibe in Statin Users, Study Finds
New data indicates obicetrapib monotherapy could provide a synergistic benefit on lipid particles when used in combination with ezetimibe in people already on high-intensity statin therapy.
The presentation, which was delivered at the American College of Cardiology 2024 (ACC.24) Annual Scientific Session, comes just 2 days prior to New Amsterdam’s announcing their phase 3 outcomes trial of the agent, named PREVAIL, had met its target enrollment of more than 9000 patients.
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
